Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial
Open accessThe DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Randomized treatment comparing an intensive glycemic treatment strategy with a standard strategy in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was ended early because of an unexpected excess of mortality in the intensive arm. As part of ongoing post hoc analyses of potential mechanisms for this finding, we explored whether on-treatment A1C itself had an independent relationship with mortality. RESEARCH DESIGN AND METHODS: Participants with type 2 diabetes (n = 10,251 with mean age 62 years, median duration of diabetes 10 years, and median A1C 8.1%) were randomly assigned to treatment strategies targeting either A1C <6.0% (intensive) or A1C 7.0–7.9% (standard). Data obtained during 3.4 (median) years of follow-up before cessation of intensive treatment were analyzed using several multivariable models. RESULTS: Various characteristics of the participants and the study sites at baseline had significant associations with the risk of mortality. Before and after adjustment for these covariates, a higher average on-treatment A1C was a stronger predictor of mortality than the A1C for the last interval of follow-up or the decrease of A1C in the first year. Higher average A1C was associated with greater risk of death. The risk of death with the intensive strategy increased approximately linearly from 6–9% A1C and appeared to be greater with the intensive than with the standard strategy only when average A1C was >7%. CONCLUSIONS: These analyses implicate factors associated with persisting higher A1C levels, rather than low A1C per se, as likely contributors to the increased mortality risk associated with the intensive glycemic treatment strategy in ACCORD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The potential risks of intensive glycemic control may be obviated by incorporating agents that are not associated with hypoglycemia, especially in persons with frequent severe hypoglycemia, hypoglycemia unawareness, or a very long duration of DM, and particularly in the presence of established and advanced atherosclerosis, advanced age, and terminal illness.69,70,76–81”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [80]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A corollary of this issue is the safety of those therapies in view of the demonstrated increase of frequency of severe hypoglycemia during attempts at intensive glycemic control.70,76,80,85,86”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [80]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These trials have more or less uniformly demonstrated a benefit, with lifestyle more efficacious than all medications with the exception of the thiazolidinediones140–152.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [148]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 1×
“This association, not taking into consideration the glycemic treatment strategy, is similar to the 12 and 14% increments of mortality associated with 1% higher average A1C in epidemiologic analyses from other studies (6,19).”
ResultEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Flexible smoothing with B-splines and penalties
Eilers, P. H. C., & Marx, B. D. (1996) · Statistical Science · doi:10.1214/ss/1038425655 · Cited by 3,666 · cited 1×
“Curves modeling the relationships over the range of observed A1C values (penalized B-splines) (17,18) were used to explore the linearity assumption in the Cox proportional hazards model.”
MethodDiabetes and Cardiovascular Disease: The Framingham Study
Kannel, W. B. (1979) · JAMA · doi:10.1001/jama.1979.03290450033020 · Cited by 2,936
Coutinho, M., Gerstein, H. C., Wang, Y., & Yusuf, S. (1999) · Diabetes Care · doi:10.2337/diacare.22.2.233 · Cited by 1,685
Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F. L., Powe, N. R., & Golden, S. H. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00007 · Cited by 1,657
Hurvich, C. M., Simonoff, J. S., & Tsai, C.-L. (1998) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00125 · Cited by 1,241 · cited 1×
“Curves modeling the relationships over the range of observed A1C values (penalized B-splines) (17,18) were used to explore the linearity assumption in the Cox proportional hazards model.”
MethodSkyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Diabetes Care · doi:10.2337/dc08-9026 · Cited by 881
Self-citation
Cited by
Items 101–200 of 404
Shah, H. S., Gao, H., Morieri, M. L., Skupien, J., Marvel, S., Paré, G., Mannino, G. C., Buranasupkajorn, P., Mendonca, C., Hastings, T., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0285 · Cited by 60
“The modulatory effect of these geneticmarkers was independent of previously identified predictors of excess mortality in the ACCORD intensive arm, such as presence of neuropathy, aspirin use, and a high HbA1c at baseline (7,10).”
BackgroundSelf-citationvan Steen, S. C. J., Schrieks, I. C., Hoekstra, J. B. L., Lincoff, A. M., Tardif, J., Mellbin, L., Rydén, L., Grobbee, D. E., DeVries, J. H., & on behalf of the AleCardio study group (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317692664 · Cited by 59
Iqbal, A., & Heller, S. R. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.004 · Cited by 64
“The ACCORD investigators have argued that there is scant evidence linking severe hypoglycaemia to increased CV mortality in the intensive glycaemic control arm of their trial, since they observed no direct relationship between severe hypoglycaemic episodes and subsequent deaths (53).”
BackgroundClinical Implications of the ACCORD Trial
Genuth, S., & Ismail-Beigi, F. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1679 · Cited by 56
Mattila, T., & de Boer, A. (2010) · Drugs · doi:10.2165/11585220-000000000-00000 · Cited by 69
“The results indicate that intensive treatment had a higher effect on mortality in patients with, for example, cardiac autonomic dysfunction, higher average HbA1c level during treatment, [31] history of neuropathy, higher HbA1c level or aspirin treatment.”
ResultA1C targets should be personalized to maximize benefits while limiting risks
Riddle, M. C., Gerstein, H. C., Holman, R. R., Inzucchi, S. E., Zinman, B., Zoungas, S., & Cefalu, W. T. (2018) · Diabetes Care · doi:10.2337/dci18-0018 · Cited by 54
Self-citationCardiovascular protection in type 2 diabetes: Insights from recent outcome trials
Bailey, C. J., & Marx, N. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13492 · Cited by 62
“able mostly to individuals who actually exhibited poor glycaemic control.(10) Until 2008, the approval of new agents to treat diabetes focused almost exclusively on glucose-lowering efficacy.”
BackgroundHbA1c and all-cause mortality risk among patients with type 2 diabetes
Li, W., Katzmarzyk, P. T., Horswell, R., Wang, Y., Johnson, J., & Hu, G. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.09.070 · Cited by 53
“The most likely culprit has been hypoglycemia, even though the post hoc analyses of ACCORD data have suggested that this is not the case [32, 33].”
Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?
Giorgino, F., Home, P. D., & Tuomilehto, J. (2016) · Diabetes Care · doi:10.2337/dcs15-3023 · Cited by 54
“In ACCORD, excess mortality was found in those who showed an increase in HbA1c with intensive glucose control (39); thus, people with worsening glycemic control when exposed to intensive treatment should be set less stringent glucose targets.”
BackgroundEffect of Intensive Glycemic Lowering on Health-Related Quality of Life in Type 2 Diabetes
Anderson, R. T., Narayan, K. M. V., Feeney, P., Goff, D., Ali, M. K., Simmons, D. L., Sperl-Hillen, J.-A., Bigger, T., Cuddihy, R., O'Conner, P. J., et al. (2011) · Diabetes Care · doi:10.2337/dc10-1926 · Cited by 53
Self-citationHypoglycemia From a Cardiologist's Perspective
Sanon, V. P., Sanon, S., Kanakia, R., Hu, Y., Araj, F., OLIVEROS, R. A., & CHILTON, R. J. (2014) · Clinical Cardiology · doi:10.1002/clc.22288 · Cited by 58
Overall Mortality in Diabetes Mellitus: Where Do We Stand Today?
DAILEY, G. E. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0019 · Cited by 60
“…that a moderate or large reduction in A1c over the first year of treatment was associated with similar rates of mortality in both the intensive and conventional treatment arms, whereas higher mortality rates were seen with intensive treatment when little or no reduction in A1c occurred 26 (Fig.”
InfluentialIndividualizing Targets and Tactics for High-Risk Patients With Type 2 Diabetes
Riddle, M. C., & Karl, D. M. (2012) · Diabetes Care · doi:10.2337/dc12-0650 · Cited by 51
Self-citationHigh hemoglobin A1c levels within the non‐diabetic range are associated with the risk of all cancers
Goto, A., Noda, M., Sawada, N., Kato, M., Hidaka, A., Mizoue, T., Shimazu, T., Yamaji, T., Iwasaki, M., Sasazuki, S., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29917 · Cited by 51
Prevention and Treatment of Diabetic Retinopathy: Evidence from Clinical Trials and Perspectives
Abbate, M., Cravedi, P., Iliev, I. P., Remuzzi, G., & Ruggenenti, P. L. (2011) · Current Diabetes Reviews · doi:10.2174/157339911795843168 · Cited by 58
Guo, T., Liu, T., Sun, Y., Liu, X., Xiong, R., Li, H., Li, Z., Zhang, Z., Tian, Z., & Tian, Y. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1695-x · Cited by 51
Mannucci, E., & Monami, M. (2017) · Advances in Therapy · doi:10.1007/s12325-016-0432-4 · Cited by 49
“While trials with less favorable CV outcomes have tended to be those in which the risk of severe hypoglycemia associated with treatment intensification is greater [60], post hoc analysis of ACCORD data indicate that it may be factors relating to a persistent average HbA1c greater than 7% that are associated with exces…”
BackgroundRutter, M. K., & Nesto, R. W. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr154 · Cited by 58
Li, F.-R., Zhang, X.-R., Zhong, W.-F., Li, Z., Gao, X., Kraus, V. B., Lv, Y., Zou, M., Chen, G., Chen, P., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02536 · Cited by 48
Individualized glycaemic targets and pharmacotherapy in type 2 diabetes
Bailey, C. J., Aschner, P. J., Prato, S. D., LaSalle, J. R., Ji, L., Matthaei, S., & Management, O. B. O. T. G. P. F. E. D. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164113490765 · Cited by 51
Insulin therapy, weight gain and prognosis
Hodish, I. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13367 · Cited by 48
“Supporting the assertion that the difference in the scientific questions was the cause for the difference in the results is a sub-analysis that applied the CREDIT methodology to the results of the ACCORD study.(51) Accumulating participants from all the ACCORD study arms, a 1% lower average HbA1c during the study was…”
Hypoglycemia in diabetes: The dark side of diabetes treatment. A patient‐centered review
Johnson‐Rabbett, B., & Seaquist, E. R. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12933 · Cited by 55
Self-citationCardiovascular Benefits of Exogenous Insulin
Chaudhuri, A., Dandona, P., & Fonseca, V. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1112 · Cited by 47
Polonsky, K. S., & Burant, C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00031-9 · Cited by 73
Lapolla, A., Mosca, A., & Fedele, D. (2011) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2011.02.006 · Cited by 49
Rensing, K. L., Reuwer, A. Q., Arsenault, B. J., von der Thüsen, J. H., Hoekstra, J. B. L., Kastelein, J. J. P., & Twickler, T. B. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01468.x · Cited by 49
“This implies that factors associated with persistent higher HbA1c levels under intensive antidiabetic treatment might have contributed to increased mortality risk [15].”
BackgroundAlexopoulos, A.-S., Yancy, W. S., Edelman, D., Coffman, C. J., Jeffreys, A. S., Maciejewski, M. L., Voils, C. I., Sagalla, N., Barton Bradley, A., Dar, M., et al. (2021) · Chronic Illness · doi:10.1177/1742395319884096 · Cited by 44
“Notably, the intensive control arm in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study experienced higher mortality, an effect that was concentrated in a subgroup of patients who remained “resistant” to HbA1c lowering despite protocol-driven regimen intensification.(12,13) This finding highlights t…”
BackgroundSchoenaker, D. A. J. M., Simon, D., Chaturvedi, N., Fuller, J. H., Soedamah-Muthu, S. S., & the EURODIAB Prospective Complications Study Group (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2824 · Cited by 43
“Other unmeasured factors in our study that may influence the association between low HbA1c and increased mortality include lack of adherence to medical advice, psychiatric conditions, cognitive function, social or financial crisis (19), hypertension, hypokalemia, QT interval (27), anemia, or other states of increased…”
BackgroundVenkataraman, K., Kao, S. L., Thai, A. C., Salim, A., Lee, J. J. M., Heng, D., Tai, E. S., & Khoo, E. Y. H. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03599.x · Cited by 45
Seidu, S., Achana, F. A., Gray, L. J., Davies, M. J., & Khunti, K. (2016) · Diabetic Medicine · doi:10.1111/dme.12885 · Cited by 43
The Impact of Hypoglycemia on the Cardiovascular System: Physiology and Pathophysiology
Yang, S., Park, K., & Zhou, Y.-J. (2015) · Angiology · doi:10.1177/0003319715623400 · Cited by 55
Predicting Cardiovascular Risk in Type 2 Diabetes: the Heterogeneity Challenges
Gore, M. O., McGuire, D. K., Lingvay, I., & Rosenstock, J. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0607-7 · Cited by 48
Freedman, B. I. (2012) · Diabetes Care · doi:10.2337/dc12-0027 · Cited by 42
Addressing the Burden of Diabetes
Seaquist, E. R. (2014) · JAMA · doi:10.1001/jama.2014.6451 · Cited by 38
Self-citationAronson, R., Orzech, N., Ye, C., Goldenberg, R., & Brown, V. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12257 · Cited by 38
“Furthermore, retrospective analyses of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial have suggested that persistent non-responders to intensive treatment, who resemble our cohort of functionally refractory patients, show an increased risk of death.(15) Partially based on this finding, current gu…”
Counterpoint: Intensive Glucose Control and Mortality in ACCORD—Still Looking for Clues
Riddle, M. C. (2010) · Diabetes Care · doi:10.2337/dc10-1658 · Cited by 38
Self-citationInsulin Dose and Cardiovascular Mortality in the ACCORD Trial
Siraj, E. S., Rubin, D. J., Riddle, M. C., Miller, M. E., Hsu, F., Ismail‐Beigi, F., Chen, S.-H., Ambrosius, W. T., Thomas, A., Bestermann, W. H., et al. (2015) · Diabetes Care · doi:10.2337/dc15-0598 · Cited by 42
Self-citationInsulin and Its Cardiovascular Effects: What Is the Current Evidence?
Dongerkery, S. P., Schroeder, P. R., & Shomali, M. E. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0955-3 · Cited by 38
Aroda, V. R., & Eckel, R. H. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14830 · Cited by 43
“with HbA1c (from 42 to 75 mmol/mol) and was highest in those unable to achieve target glycaemia (HbA1c < 53 mmol/mol).(84) Separate analyses have confirmed that intensive therapy increases the risk of severe hypoglycaemia by two- to threefold(85-89) and a metaanalysis showed a correlation between risk of severe hypogl…”
BackgroundIntensive insulin for type 2 diabetes: the risk of causing harm
Nolan, C. J., Ruderman, N. B., & Prentki, M. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70027-5 · Cited by 37
SGLT inhibitors as antidiabetic agents: a comprehensive review
Kshirsagar, R. P., Kulkarni, A. A., Chouthe, R. S., Pathan, S. K., Une, H. D., Reddy, G. B., Diwan, P. V., Ansari, S. A., & Sangshetti, J. N. (2020) · RSC Advances · doi:10.1039/c9ra08706k · Cited by 45
Schwartz, S. S., & Kohl, B. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0468 · Cited by 40
Chamarthi, B., Gaziano, J. M., Blonde, L., Vinik, A. I., Scranton, R. E., Ezrokhi, M., Rutty, D., & Cincotta, A. H. (2015) · Journal of Diabetes Research · doi:10.1155/2015/157698 · Cited by 36
Home, P., Shen, C., Hasan, M. I., Latif, Z. A., Chen, J.-W., & González-Gálvez, G. (2014) · Diabetes Care · doi:10.2337/dc13-2413 · Cited by 38
“Unfortunately, we know from the ACCORD epidemiological analysis that people who fail to improve control with intensification of therapy (including insulin presumably) have poor outcomes (33), but it appears from our analysis that the factors measured here, including macrovascular complications and prior hypoglycemia,…”
BackgroundLiebl, A., Jones, S., Benroubi, M., Castell, C., Goday, A., Aline Charles, M., Smith, H. T., Nicolay, C., & Simpson, A. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.555755 · Cited by 35
Stoekenbroek, R. M., Rensing, K. L., Moens, S. J. B., Nieuwdorp, M., DeVries, J. H., Zwinderman, A. H., Stroes, E. S. G., Currie, C. J., & Hutten, B. A. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.03.040 · Cited by 38
Østergaard, H. B., Mandrup-Poulsen, T. R., Berkelmans, G. F. N., van der Graaf, Y., Visseren, F. L. J., & Westerink, J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.04.006 · Cited by 33
Platelet function following induced hypoglycaemia in type 2 diabetes
Kahal, H., Aburima, A. A., Spurgeon, B. E. J., Wraith, K. S., Rigby, A. S., Sathyapalan, T., Kilpatrick, E. S., Naseem, K. M., & Atkin, S. L. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.04.004 · Cited by 34
Pfister, R., Sharp, S. J., Luben, R., Khaw, K.-T., & Wareham, N. J. (2011) · Diabetologia · doi:10.1007/s00125-011-2162-0 · Cited by 35
“However, recent post hoc analyses of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial also suggested that a subgroup of patients with refractory hyperglycaemia accounts for the increased mortality risk observed with the intensive treatment strategy in diabetic patients and not ordinary lower glycae…”
ResultFreemantle, N., Danchin, N., Calvi-Gries, F., Vincent, M., & Home, P. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12598 · Cited by 30
“The CREDIT population improved glucose control markedly with the insulin therapy as above, so it is possible we are looking mainly at the comparatively benign type of hypoglycaemia associated with optimization of control with insulin, rather than the more malign type that marks concomitant illness [6,9].”
BackgroundResultInfluentialBrown, J. B., Reichert, S. M., Valliere, Y., Webster-Bogaert, S., Ratzki‐Leewing, A. A., Ryan, B. L., & Harris, S. B. (2019) · Diabetes Spectrum · doi:10.2337/ds18-0074 · Cited by 38
“The most well-documented emotional response is fear of hypoglycemia, which can be so intense that individuals deliberately maintain blood glucose levels above target (12,21,24,32).”
BackgroundEdward, J. A., Josey, K., Bahn, G., Caplan, L., Reusch, J. E. B., Reaven, P. D., Ghosh, D., & Raghavan, S. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01496-7 · Cited by 33
“Prior secondary analyses of the ACCORD study suggest that features of ontrial HbA1c may be associated with trial outcomes [42, 44]– an approach that contrasts with our study focused on baseline characteristics in which HbA1c was not used in the summary decision tree.”
ResultSedlić, F., Muravyeva, M., Šepac, A., Sedlić, M., Williams, A. M., Yang, M., Bai, X., & Bosnjak, Z. J. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25413 · Cited by 31
“However, it was also reported that high glucose itself can inducepreconditioning (Schaffer et al., 2000).”
BackgroundUnderstanding Low Sugar from NICE-SUGAR
Hirsch, I. B. (2012) · New England Journal of Medicine · doi:10.1056/nejme1208208 · Cited by 31
Handelsman, Y. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01054-w · Cited by 34
Nahmias, A., Stahel, P., Xiao, C., & Lewis, G. F. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00100 · Cited by 31
“Furthermore, the risk of death appeared to be greater with the intensive compared to the standard strategy only when the average HbA1c was >7% (57).”
BackgroundGlycemic Control and Cardiovascular Disease: What’s a Doctor to Do?
Kishore, P., Kim, S. H., & Crandall, J. P. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0268-5 · Cited by 33
“Further, in a post hoc analysis, higher (not lower) mean on-treatment HbA1c was a significant predictor of mortality, an effect that appeared to be greater in the intensive treatment group [47].”
BackgroundThe Abu Dhabi Cardiovascular Program: The Continuation of Framingham
Hajat, C., & Harrison, O. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2010.05.002 · Cited by 29
“They may also be downstream such as HbA1c control in known diabetics; a 1% increase in HbA1c is known to increase risk of all-cause mortality by as much as 66%.(26) Numerous other iterations of risk exist and are routinely monitored through the Abu Dhabi approach.”
BackgroundBuse, J. B., Polonsky, K. S., & Burant, C. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00031-6 · Cited by 50
Self-citationControversies in the cardiovascular management of type 2 diabetes
Opie, L. H., Yellon, D. M., & Gersh, B. J. (2010) · Heart · doi:10.1136/hrt.2010.214031 · Cited by 31
“For example, a post hoc and non-prespecified analysis of ACCORD hypothesises that there were systemic factors associated with persisting HbA1C values$7, such as serious associated medical or social or cognitive problems beyond DM2.”
InfluentialLeong, A., Berkowitz, S. A., Triant, V. A., Porneala, B., He, W. W., Atlas, S. J., Wexler, D. J., & Meigs, J. B. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3169 · Cited by 27
Cardoso, C. R. L., Leite, N. C., Ferreira, M. T., & Salles, G. F. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0592-0 · Cited by 27
“Our results corroborate these post hoc analyses of the ACCORD trial [28].”
MethodResultClemson University, C. E. S. (2006) · Oxford University Press eBooks · doi:10.1093/med/9780199543724.001.0001 · Cited by 28
Translating What Works: A New Approach to Improve Diabetes Management
Phillips, L. S., Barb, D., Yong, C., Tomolo, A. M., Jackson, S. L., Olson, D. E., Rhee, M. K., Duva, I. M., He, Q., & Long, Q. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815576000 · Cited by 25
“(Increased A1c variability was associated with increased mortality in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation [ADVANCE] trial,(48) and may have increased mortality and led to early termination in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study.(…”
BackgroundBritton, K. A., Aggarwal, V., Chen, A. Y., Alexander, K. P., Amsterdam, E. A., Fraulo, E. S., Muntner, P., Thomas, L. E., McGuire, D. K., Wiviott, S. D., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2010.12.004 · Cited by 26
Odawara, M., Ohtani, T., & Kadowaki, T. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0220 · Cited by 26
Scavini, M., Bosi, E., Ceriello, A., Giorgino, F., Porta, M., Tiengo, A., Vespasiani, G., Bottalico, D., Marino, R., Parkin, C., et al. (2013) · Acta Diabetologica · doi:10.1007/s00592-011-0357-y · Cited by 25
“However, in patients with a high cardiovascular risk, an intensive management of diabetes targeting normal glycated hemoglobin (HbA1c) levels with the use of multiple diabetes medications is associated with higher mortality than is a standard approach targeting higher HbA1c levels [6, 7].”
BackgroundGlucose control in diabetes: which target level to aim for?
Laakso, M., & Cederberg, H. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02528.x · Cited by 29
Low HbA1c and mortality: causation and confounding
Rutter, M. K. (2012) · Diabetologia · doi:10.1007/s00125-012-2620-3 · Cited by 26
“Decisions about optimal clinical HbA1c targets should be guided mainly by the results of clinical trials involving a Low HbA1c in observational studies b Low HbA1c in the ACCORD trial [27]”
BackgroundMethodManagement of Type 2 Diabetes: Implications for the Home Healthcare Clinician
Rudy Bilous MD, F., Donnelly, R., & Iskandar Idris DM, F. (2002) · Wiley eBooks · doi:10.1002/9781118976074.ch11 · Cited by 24
Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitus
Ikeda, M., & Shimazawa, R. (2019) · Journal of General and Family Medicine · doi:10.1002/jgf2.244 · Cited by 28
Aronson, R., Orzech, N., Ye, C., Brown, R. E., Goldenberg, R., & Brown, V. (2016) · Diabetes Care · doi:10.2337/dc15-2666 · Cited by 23
Schwartz, S. S., Jellinger, P. S., & Herman, M. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1191955 · Cited by 24
Cardiovascular effects of anti-diabetes drugs
Younk, L. M., Lamos, E. M., & Davis, S. N. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1195368 · Cited by 24
“However, in a follow-up of ACCORD, the increased mortality in the intensive group was not able to be explained by the difference in symptomatic severe hypoglycemia [164,165].”
BackgroundAnyanwagu, U., Mamza, J., Donnelly, R., & IDRIS, I. R. (2018) · Age and Ageing · doi:10.1093/ageing/afy178 · Cited by 28
Overcoming Obstacles in Risk Factor Management in Type 2 Diabetes Mellitus
Handelsman, Y., & Jellinger, P. S. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00490.x · Cited by 23
“0%.(40) A consensus statement by the American Diabetes Association”
BackgroundWhat matters in ADVANCE and ADVANCE‐ON
Hamet, P. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01509.x · Cited by 27
“Posthoc epidemiological analyses of the ACCORD study showed that the increased mortality was associated with higher average HbA1c [23].”
BackgroundResultGlaser, E., Richard, C., & Lussier, M. (2017) · Patient Education and Counseling · doi:10.1016/j.pec.2017.05.022 · Cited by 24
Rhee, S. Y. (2017) · Endocrinology and Metabolism · doi:10.3803/enm.2017.32.2.195 · Cited by 21
Strategies to Prioritize Clinical Options in Primary Care
O’Connor, P. J., Sperl‐Hillen, J. M., Margolis, K. L., & Kottke, T. E. (2017) · The Annals of Family Medicine · doi:10.1370/afm.2027 · Cited by 24
Self-citationGolden, S. H. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.017 · Cited by 28
Giaccari, A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13814 · Cited by 23
“Although the absence of cardiovascular benefits in these trials (focused on achieving close to normal glycated haemoglobin [HbA1c]) has been attributed to an increase in hypoglycaemic episodes (all these trials were mostly conducted with sulphonylureas and/or insulin), a clear relation between hypoglycaemia and increa…”
ResultShould A1C Targets Be Individualized for All People With Diabetes?
Teoh, H., Home, P., & Leiter, L. A. (2011) · Diabetes Care · doi:10.2337/dc11-s217 · Cited by 23
“Thus, it appears that contrary to expectation, whereas hypoglycemia was higher in the intensively managed group, in both groups, more hypoglycemia was found at higher rather than at lower A1C levels (25).”
ResultAndrews, S. M., Sperber, N. R., Gierisch, J. M., Danus, S. M., Macy, S., Bosworth, H. B., Edelman, D. E., & Crowley, M. J. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s125673 · Cited by 22
“1 year, despite clinic-based care,(5) contribute disproportionately to the nationwide diabetes burden.(6,7) The prevalence of PPDM is ~10% of US adults with diabetes.”
Point: Intensive Glycemic Control and Mortality in ACCORD—A Chance Finding?
Lachin, J. M. (2010) · Diabetes Care · doi:10.2337/dc10-1506 · Cited by 20
“Glycemia (A1C) Since intensive therapy was designed to lower glucose, as measured by A1C, an association with A1C was carefully explored in further epidemiological analyses (7).”
BackgroundMethodMicrovascular complications and frailty can predict adverse outcomes in older patients with diabetes
Sable‐Morita, S., Tanikawa, T., Satake, S., Okura, M., Tokuda, H., & Arai, H. (2021) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.14142 · Cited by 21
Individualizing treatment targets in diabetes care
Buse, J. B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.230 · Cited by 18
“In May 2010, Riddle and colleagues published an epidemiologic analysis from ACCORD that examined the relationship between on-treatment HbA 1c levels and mortality”
BackgroundSelf-citationHirsch, I. B., Amiel, S. A., Blumer, I. R., Bode, B. W., Edelman, S. V., Seley, J. J., Verderese, C. A., & Kilpatrick, E. S. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0132 · Cited by 18
“36 More vigi-lant monitoring of glycemic variability (as a predictor of hypoglycemia) may therefore be warranted in patients with diabetes at high risk for cardiovascular disease.”
Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?
Zannad, F. M., Stough, W. G., Pocock, S., Sleight, P., Cushman, W. C., Cleland, J. G. F., McMurray, J. J. V., Lonn, E., Geller, N. L., Wedel, H., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr437 · Cited by 19
Meneilly, G. S., Berard, L., CHENG, A. Y. Y., Lin, P., MacCallum, L., Tsuyuki, R. T., Yale, J., Nasseri, N., Richard, J.-F., Goldin, L., et al. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.03.003 · Cited by 20
Alatorre, C., Hoogwerf, B. J., Deeg, M. A., Nelson, D. R., Hunter, T. M., Ng, W. T., & Rekhter, M. D. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1396969 · Cited by 18
Major rapid weight loss induces changes in cardiac repolarization
Vedel-Larsen, E., Iepsen, E. W., Lundgren, J., Graff, C., Struijk, J. J., Hansen, T., Holst, J. J., Madsbad, S., Torekov, S., & Kanters, J. K. (2016) · Journal of Electrocardiology · doi:10.1016/j.jelectrocard.2016.02.005 · Cited by 17
Evolving Treatment Strategies for the Management of Type 2 Diabetes
Cefalu, W. T. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31823ea4af · Cited by 20
Risks and benefits of attaining HbA(1c) goals: examining the evidence.
Shubrook, J. H., & Shubrook, J. H. (2010) · PubMed · Cited by 17
International Diabetes Center Treatment of Type 2 Diabetes Glucose Algorithm
Simonson, G., Cuddihy, R. M., Reader, D., & Bergenstal, R. M. (2011) · Diabetes Management · doi:10.2217/dmt.10.22 · Cited by 21
Sluik, D., Boeing, H., Montonen, J., Kaaks, R., Lukanova, A., Sandbæk, A., Overvad, K., Arriola, L., Ardanáz, E., Saieva, C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038877 · Cited by 19
“Recent findings from a randomized controlled trial [10,28] and an observational study [9] have suggested that the association between HbA1c and mortality might be U-shaped, i.”
BackgroundBataille, V., Ferrières, J., Danchin, N., Puymirat, É., Zeller, M., Simon, T., & Carrié, D. (2017) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872617719639 · Cited by 20
The Swedish National Diabetes Register in clinical practice and evaluation in primary health care
Hallgren, I.-M., Grodzinsky, E., & Törnvall, E. (2016) · Primary Health Care Research & Development · doi:10.1017/s1463423616000098 · Cited by 17
“A triangulation method was used in the study, incorporating the sequential data analysis of a questionnaire, statistics and interviews (Östlund et al., 2011).”
MethodType 2 diabetes: cost-effectiveness of medication adherence and lifestyle interventions
Nerat, T., Locatelli, I., & Kos, M. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s114602 · Cited by 20
“Furthermore, the mortality rate increased linearly from 6% to 9% HbA1c.10 The positive effect of a lower HbA1c on cardiovascular complications (the United Kingdom Prospective Diabetes Study [UKPDS], HOPE study) was also detected in long-term epidemiological studies.11–14 The intervention results in type 2 diabetes pat…”
A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment
Mariam, A., Miller-Atkins, G. A., Pantalone, K. M., Zimmerman, R. S., Barnard, J., Kattan, M. W., Shah, H., McLeod, H. L., Doria, A., Wagner, M. J., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2700 · Cited by 19
Self-citation
Metadata
- Authors
- Riddle, M. C., Ambrosius, W. T., Brillon, D. J., Buse, J. B., Byington, R. P., Cohen, R. M., Goff, D. C., Malozowski, S., Margolis, K. L., Probstfield, J. L., Schnall, A., Seaquist, E. R., & for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Investigators
- Affiliations
- Oregon Health & Science University (US)
- Wake Forest University Health Sciences (US)
- Cornell University (US)
- University of North Carolina at Chapel Hill (US)
- University of Cincinnati (US)
- National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland;
- HealthPartners (US)
- University of Washington (US)
- Case Western Reserve University (US)
- University of Minnesota (US)
- Corresponding author
- Riddle, Matthew C.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-05-01
- Volume
- 33
- Issue
- 5
- Pages
- 983-990
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2858202
- OpenAlex
- W2078241682
- Cited by
- 406
- References
- 21
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 9 · 2023: 12 · 2022: 13 · 2021: 13 · 2020: 18 · 2019: 25 · 2018: 26 · 2017: 31 · 2016: 27 · 2015: 37 · 2014: 28 · 2013: 30 · 2012: 40
- FWCI
- 38.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, n01hc95178-28-0-1, n01hc95179-25-0-0)
- National Heart, Lung, and Blood Institute (N01- HC-95181, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, IAAY1-HC-1010, IAA #Y1-HC-9035, N01 HC095180, Y01 HC009035, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- HbA1c, all-cause mortality, tight glycemic control, type 2 diabetes, ACCORD trial, mortality risk
- MeSH terms
- Aged, Cause of Death, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemic Agents, Male, Middle Aged, Risk Factors, Multivariate Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.